|
FOREIGN AGENCY AGREEMENT
国外代理协议 KNOW ALL MEN BY THESE PRESENTS: This FOREIGN AGENCY AGREEMENT (the “Agreement”) is made and entered, into by and amongst: 本国外代理协议（以下简称“协议”）由以下人员签署并签署： XXX Co Ltd, a foreign company existing and duly registered under the laws of China, with principal address at XXX, China, hereinafter referred to as “MANUFACTURER”. XXX有限公司，一家外国公司，根据中国法律正式注册，主要地址为中国XXX，以下简称“制造商”。 XXX Co Ltd., a corporation duly organized and existing under the laws of China, with official place of business at XXX. China, hereinafter referred to as “EXPORTER” ,represented in this act by its General Manager , MR.XXX. XXX有限公司是一家根据中国法律正式组建和存续的公司，官方营业地点位于吉林省XXX，以下简称 “出口商”，由其副总经理，杨XXX先生代表。 -and- XXX INC, a domestic corporation duly registered and existing under the laws of the Philippines, with office address at XXX, PHILIPPINES, hereinafter referred to as “DISTRIBUTOR”, represented in this act by its Chief Executive Officer ( CEO) Mr. XXX. WITNESSETH That: WHEREAS, MANUFACTURER is a duly organized corporation existing under the laws of China and is a licensed manufacturing company where the manufacturer possesses manufacturing and quality control facilities used in the manufacture, repacking and analyzing different pharmaceutical products and formulations; 鉴于，制造商是一家根据中国法律成立的正式组织的公司，是一家持牌制造公司，制造商拥有制造和质量控制设施，用于制造，重新包装和分析不同的药品和配方; WHEREAS, DISTRIBUTOR is a domestic corporation duly organized and existing under the laws of the Philippines, and possesses a license to operate as drug importer/distributor issued by the Philippine Food and Drug Administration, wishes to engage the services and avail of the pharmaceutical products of the Supplier and distribute the same under its own brand name and trademark; 鉴于，经销商是一家根据菲律宾法律正式组建和存在的国内公司，并拥有菲律宾食品药品管理局颁发的药品进口商/分销商的经营许可，希望获得服务和利用的药品。 供应商并以自己的品牌和商标分销; NOW THEREFORE, premises considered, the parties agree as follows: 因此，在考虑前提时，各方同意如下： 1. APPOINTMENT 约定 Subject to the terms and conditions of this Product Distribution Agreement, MANUFACTURER appoints DISTRIBUTOR, and DISTRIBUTOR accepts such appointment and agrees to act as MANUFACTURER’s distributor of the SUPPLIER’s Products set forth in the Product List (Annex “A”) within the geographical territory defined as follows: The Whole of Philippine Archipelago/Island. 根据本产品经销协议的条款和条件，制造商任命经销商，经销商接受此类委任，并同意作为制造商在所定义的地理区域内的产品清单（附件“A”）中规定的供应商产品的分销商。 如下：整个菲律宾群岛/岛屿。 2. PRODUCT LIST: [Annex “A”] 产品清单 2.1 The products listed in Annex “A” of this Agreement may be amended or deleted by written agreement/consent of all parties. Any written amendment or deletion in writing shall form part of the original agreement and binding upon both parties during its term. 2.1本协议附件“A”中列出的产品可以通过所有各方的书面协议/同意进行修改或删除。 任何书面修改或书面删除均构成原协议的一部分，并在双期内对双方均有约束力。 2.2 The prices as agreed by MANUFACTURER/ EXPORTER and DISTRIBUTOR may be reviewed and renegotiated from time to time or as the need arises upon written request of any one of the paries, thirty (30) days prior to the intended date of review or renegotiation. Should there be a need to change the prices of any of the products covered by this agreement, MANUFACTURER/ EXPORTER must notify DISTRIBUTOR in writing of such proposed change within thirty (30) days prior to the intended implementation for discussion/negotiation. Should the change in prices be inevitable, DISTRIBUTOR may make a last order equivalent to the quantity of the latest order at the current price prior to such change. 2.2制造商/出口商和经销商商定的价格可能会在预定的审查或重新谈判日期之前三十（30）天内不时或根据任何一个要求的书面请求进行审查和重新谈判。 如果需要更改本协议涵盖的任何产品的价格，制造商/出口商必须在预定实施之前的三十（30）天内以书面形式通知经销商，以进行讨论/谈判。 如果价格变化不可避免，分销商可能会在此类变更之前以当前价格做出最新订单的最后订单。 3. REGISTRATION AND USE OF TRADEMARKS/BRAND NAME 商标/商品名的注册和使用 3.1 MANUFACTURER/ EXPORTER shall provide all the necessary registration documents/materials required by the Philippine Food and Drug Administration (FDA) upon the request of DISTRIBUTOR, and shall bear all the expenses for providing such documents, including but not limited to Authenticated copies of Certificate of Free Sale(CFS), current Good Manufacturing Practice (cGMP), Certificate from China and Philippine FDA, original copies of Certificates of Pharmaceutical Products ( CoPPs), product dossiers, product samples and satisfactory Bioequivalence / Biowaiver Reports whichever is applicable (if required) , etc. MANUFACTURER shall bear all expenses for the completion of all registration requirements. 3.1制造商/出口商应根据经销商的要求提供菲律宾食品药品管理局（FDA）要求的所有必要的登记文件/材料，并应承担提供此类文件的所有费用，包括但不限于经过认证的证书副本。 自由销售证书（CFS），现行良好生产规范证书（cGMP），中国和菲律宾FDA证书，药品销售证书（CoPP）原始副本，产品档案，产品样本和令人满意的生物等效性/生物豁免报告（如果需要） 制造商应承担完成所有注册要求的所有费用。 3.2 DISTRIBUTOR shall register the products with the Philippine FDA using its own brand name/trademark and indicating MANUFACTURER as its manufacturer, and shall bear all the expenses for registration of the products stipulated in Annex “A” of this Agreement. 3.2经销商应使用自己的品牌/商标向菲律宾FDA注册产品，并指明制造商为制造商，并承担本协议附件“A”中规定的产品注册的所有费用。 3.3 MANUFACTURER hereby acknowledges that the brand name/trademarks used by DISTRIBUTOR for the products listed in Annex “A” are solely, exclusively, and proprietarily owned by DISTRIBUTOR, and the same may not be used by MANUFACTURER without the written and express permission of DISTRIBUTOR. 3.3制造商特此声明，经销商对附件“A”中所列产品使用的品牌名称/商标仅由经销商独家拥有，未经经销商书面明确许可，制造商不得使用该品牌/商标。。 4. ORDERS, DELIVERY AND PAYMENT 订单、交货和付款 4.1 DISTRIBUTOR shall order Products from MANUFACTURER/ EXPORTER by submitting a written purchase order identifying the products ordered with pertinent quantity and requested delivery dates. 4.1经销商应通过提交书面采购订单向制造商/出口商订购产品，该订单确定订购的产品及相关数量和要求的交货日期。 4.2 DISTRIBUTOR shall issue a confirmed Letter of Credit at sight or Telegraphic Transfer to MANUFACTURER equivalent to 100% of the amount due upon receipt of the original copy of the Bill of Lading (BL) and other relevant shipping documents. DISTRIBUTOR shall pay MANUFACTURER / EXPORTER based on the most recent agreed prices of the registered products due for shipment . 4.2经销商应向制造商发出确认信用证或电汇，确认收到提单原件（BL）和其他相关装运单据时支付应付金额的100％。 经销商应根据最近商定的注册产品的价格向制造商/出口商支付费用。 4.3 MANUFACTURER/ EXPORTER shall supply and deliver the ordered commodity to DISTRIBUTOR in not more than ninety (90) days upon placement of the written purchase order. 4.3制造商/出口商应在下达书面采购订单后不超过九十（90）天内向订购商提供和交付订购的商品。 4.4 MANUFACTURER/ EXPORTER shall ensure that each order received from DISTRIBUTOR is timely filled and that the products are delivered within the agreed delivery schedule. MANUFACTURER/ EXPORTER shall ensure that all products delivered to DISTRIBUTOR are invoiced and packed in accordance with the applicable order or instruction from DISTRIBUTOR, and all applicable laws, rules and regulations. EXPORTER shall bear the risk of loss of, or damage to the products until actual receipt, inspection and acceptance by DISTRIBUTOR. 4.4制造商/出口商应及时确认从经销商处收到的每份订单，并确保在商定的交货时间表内交付产品。 制造商/出口商应确保按照经销商的适用订单或指示以及所有适用的法律，法规和规定对交付给经销商的所有产品进行开票和包装。 在经销商实际收货，检查和验收之前，出口商应承担产品丢失或损坏的风险。 4.5 MANUFACTURER shall maintain a substantial and adequate inventory of the raw materials used in the manufacture of the products listed in Annex “A” to ensure availability of the supply of products to DISTRIBUTOR. 4.5制造商应保持用于制造附件“A”所列产品的原材料的充足和充足的库存，以确保向分销商提供产品。 5. TRANSACTIONS BETWEEN GOVERNMENT AGENCIES AND OTHERS 政府机构与其他机构之间的交易 5.1 Purchases of the Philippine Government, its subsidiaries, agencies, government owned and controlled corporations and any of its instrumentalities for the products listed in Annex “A” whether contracted through DISTRIBUTOR or not shall be referred to DISTRIBUTOR for appropriate service/sales. MANUFACTURER/ EXPORTER shall immediately inform and refer to DISTRIBUTOR any negotiation with any institutions and companies, whether government or private with regards to the sale and/or use of the said products. 5.1菲律宾政府，其子公司，代理商，政府所有和控制的公司购买附件“A”所列产品，无论是否通过经销商签订，均应转交给经销商以获得适当的服务/销售。 制造商/出口商应立即通知并向经销商询问与任何机构和公司（无论是政府还是私人）就销售和/或使用所述产品进行的任何谈判。 6. QUALITY ASSURANCE AND WARRANTY 质量保证和保证 6.1 ALL Parties are responsible for the quality of the products with MANUFACTURER / EXPORTER responsible for the manufacturing, shipping and handling quality issues, while DISTRIBUTOR is responsible for local territory handling (storage & distribution) issues. 6.1所有缔约方均对产品质量负责，制造商/出口商负责制造，运输和处理质量问题，而分销商负责当地领域内处理（储存和分销）问题。 6.2 MANUFACTURER shall manufacture/pack under internationally accepted BP/ USP/ European standards all the registered products covered by this agreement within the agreed period upon receipt of written order from DISTRIBUTOR. 6.2制造商应在收到经销商的书面订单后，在约定的期限内，按照国际公认的BP / USP /欧洲标准制造和包装本协议所涵盖的所有注册产品。 6.3 The potency of the products that will be supplied by MANUFACTURER to DISTRIBUTOR under this agreement shall not be lower than 100% of the claimed content of the active ingredient (s) as assayed upon receipt in the Philippine territory. MANUFACTURER is required to have the product assayed by APLAC Accredited Testing Laboratories. 6.3根据本协议，制造商向分销商提供的产品的效力不得低于在菲律宾境内收到的有效成分标识含量的100％。 制造商按要求提供产品，经APLAC认可的测试实验室进行分析。 6.4 MANUFACTURER shall institute the necessary quality inspection of the products covered by this agreement prior to shipment and shall provide a copy of the said analysis, and samples of the products prior to shipment, for the analysis and physical evaluation of DISTRIBUTOR. 6.4制造商应在装运前对本协议所涵盖的产品进行必要的质量检验，并在装运前提供上述质量检验的报告单和样品，以便经销商进行分析和实物评估。 6.5 MANUFACTURER warrants that the Products will be produced according to current Good Manufacturing Practices (cGMPs) standards/ regulations and in accordance with all other applicable laws. 6.5制造商保证产品将根据现行的良好生产规范（cGMPs）标准/法规并根据所有其他适用法律生产。 6.6 DISTRIBUTOR shall observe Good Storage Practices (GSP) and Good Distribution Practices (GDP) of all the products covered by this Agreement at all times to preserve the integrity of the same throughout their shelf life. 6.6经销商应始终遵守本协议涵盖的所有产品的良好存储规范（GSP）和良好分销规范（GDP），以保证其在整个保质期内的完整性。 6.7 Any complaints regarding defects in quality upon inspection and/ or shortfalls in quantities of the Products delivered by MANUFACTUER / EXPORTER shall be made in writing by DISTRIBUTOR. MANUFACTURER shall be responsible for the product’s quality within the product’s shelf life, and guarantees to replace any batch within ninety (90) days after being notified of such defect. 6.7任何关于检查时质量缺陷和/或制造商/出口商交付的产品数量不足的投诉均应由经销商以书面形式提出。 制造商应对产品的保质期内的产品质量负责，并保证在收到此类缺陷通知后九十（90）天内更换任何批次。 6.8 MANUFACTURER shall also be liable for all damages caused by the substandard products and shall compensate DISTRIBUTOR for all expenses for recall operations if the complained products need to be recalled from the market. 6.8如果投诉产品需要从市场上召回，制造商还应对不合格产品造成的所有损害承担责任，并应向经销商赔偿召回业务的所有费用。 6.9 MANUFACTURER/ EXPORTER hereby agrees to indemnify, defend and hold harmless DISTRIBUTOR, its affiliates and all officers, directors, employees and agents thereof (herein referred to as “Indemnitees”) against all liabilities, actions, suits, damages, claims losses, costs, expenses, demands, (including without limitation attorney’s fees, expenses and settlement costs) (collectively, “Damages”) arising out of or related to the manufacture, sale, or supplying of products or their use or disposition, and/or defect of the products, and by reason of MANUFACTURER’s violation, non-observance or non-compliance with GMP Standards set forth pursuant to this agreement or Phil. FDA regulations, ordinances or laws. 6.9制造商/出口商特此同意赔偿，保护和保护经销商，其关联公司及其所有高级职员，董事，雇员及其代理人（以下简称“赔偿人”）免受所有责任，诉讼，诉讼，损害赔偿，索赔损失，费用的损害。 制造，销售或供应产品或其使用或处置，和/或缺陷引起的或与之相关的，费用，要求（包括但不限于律师费，费用和结算费用）（统称“损害赔偿”） 产品，并且由于制造商违反，不遵守或不遵守本协议规定的GMP标准或菲律宾FDA法规，条例或法律。 7. EFFECTIVE DATE 生效日期 7.1 The term of this Agreement shall begin on the date when All parties signed this Agreement shall be valid for five (5) years. This Agreement may be modified or amended upon mutual agreement of all parties. Signed Amendments by all parties shall form part of the original agreement and shall be binding upon all parties concerned . 7.1本协议的有效期自各方签署本协议之日开始，有效期为五（5）年。 经双方共同协议，本协议可以修订或修改，各方签署的修正案应构成原始协议的一部分，并对所有相关方具有约束力。 8. TERMINATION 协议终止 8.1 Anyone of the parties may terminate this Agreement by giving the other parties thirty (30) days written notice upon the occurrence of any of the following: 8.1任何一方均可在发生以下任何一方后三十（30）天书面通知其他方终止本协议： a. Material breach or default as to any obligation hereunder by any one of the parties and the failure of the breaching party to promptly pursue within thirty (30) days after receiving written notice thereof from the non-breaching party a reasonable remedy designed to cure (in the reasonable judgment of the non-breaching party) such material breach or default, this Agreement may be terminated by the non-breaching party by giving written notice of termination to the breaching party. 任何一方当事人违反或违约的任何义务以及违约方未能在收到非违约方的书面通知后三十（30）天内迅速追究一项旨在治愈的合理补救措施 （根据非违约方的合理判断）此类重大违约或违约，非违约方可通过向违约方发出书面终止通知终止本协议。 b. Bankruptcy. Upon the filing of a petition in bankruptcy, insolvency or reorganization against or by any of the parties , becoming subject to a composition for creditors, whether by law or agreement, or either party going into receivership or otherwise becoming insolvent (such party hereinafter referred to as the "insolvent party"), this Agreement may be terminated by any of the parties by giving written notice of termination to the insolvent party. 破产：在提交破产，破产或重组或针对任何当事方重组时，无论是通过法律还是协议，或者任何一方进入破产管理或以其他方式破产而成为债权人的组成（以下称为 作为“破产方”），本协议可由任何一方通过向破产方发出书面终止通知而终止。 c. Change in control or management or operating personnel of either party (the "changed party"), which has, or in the reasonable opinion of the other party could have, a material adverse effect on the business, prospects or operations of such changed party and the failure of such changed party to promptly pursue within ninety (90) days after receiving written notice thereof from the other party a remedy designed to cure (in the sole judgment of the other party) the other party's objections to such change, this Agreement may be terminated by the other party by giving written notice of termination to the changed party. 任何一方(“变更方”)的控制、管理或运营人员发生变更，而该变更已或在另一方合理认为可能对业务产生重大不利影响的，前景或操作这样的改变党和这样的失败改变方立即追求后九十(90)天内收到书面通知合同另一方设计的补救治疗(另一方)的唯一判断对方的反对这种变化,可以终止本协议另一方提供书面通知终止的改变。 8.2 Upon termination of this agreement all rights and obligations of the parties hereto shall cease and terminate except as to rights and obligations accrued prior to the date of such termination. 8.2本协议终止后，除在本协议终止日期之前产生的权利和义务外，双方的所有权利和义务均应终止和终止。 8.3 In case of termination by reason of MANUFACTURER’s default, the same shall be liable for any and all damages, actual and consequential, resulting from such default and termination. 8.3如果因制造商的违约而终止，则同样应对因该违约和终止而产生的任何和所有实际的和相应的损害承担责任。 9. FORCE MAJEURE 不可抗力 9.1 Neither party shall be liable in the event that its performance of this Agreement is prevented by reason of an Act of God, labor dispute, or war (declared or undeclared) or other hostilities, or by any other event, condition or cause which is not foreseeable on the Effective Date and is beyond the reasonable control of the party. 9.1任何一方应当承担的责任,本协议的性能是由不可抗力的原因,预防劳动争议,或战争(宣布或未申报的)或其他敌对行动,或任何其他事件,条件或原因不可以预见的生效日期和超出党的合理控制。 9.2 However, the party affected by the event of Force Majeure shall inform the other party of its occurrence in writing as soon as possible and thereafter send a certificate of the event issued by the relevant authorities, to the other party within fifteen (15) days after its occurrence. All monies owed, advanced to either party shall be paid or returned upon declaration of such event at the earliest possible time allowed by the circumstances. 9.2但是，受不可抗力事件影响的一方应尽快将其发生的情况书面通知另一方，并在不可抗力事件发生后十五(15)天内将有关部门出具的不可抗力事件的证明寄给另一方。所欠任何一方的、预先支付给任何一方的所有款项，均应在情况允许的最早时间内，在宣布发生此类事件时予以支付或退还。 9.3 In the event that performance of a party is delayed for more than two (2) months, the other party shall have the right, which shall be exercisable for so long as the cause of such delay shall continue to exist, to terminate this Agreement without liability for such termination. 9.3一方迟延履行超过两(2)个月的，另一方有权终止本协议，但不承担终止责任，该权利在迟延履行的原因继续存在的情况下行使。 10. ASSIGNMENT 约定 This Agreement and the rights and obligations hereunder may not be assigned, delegated or transferred by any one of the parties without the prior written consent of the other parties. 未经其他各方事先书面同意，任何一方不得转让、委托或转让本协议及其项下的权利和义务。 11. NOTICES 通知 All notices given under this Agreement shall be in writing and shall be addressed to the parties at their respective addresses.本协议项下发出的所有通知均应以书面形式发出，并应按下述各自地址发送。 12. WAIVER 豁免条款 None of the conditions or provisions of this Agreement shall be held to have been waived by any act or knowledge on the party of any one of the parties, except by an instrument in writing signed by a duly authorized officer or representative of such party. Further, the waiver by any one of the parties of any right hereunder or the failure to enforce at any time any of the provisions of this Agreement, or any rights with respect thereto, shall not be deemed to be a waiver of any other rights hereunder or any breach or failure of performance of the other parties. 本协议任何一方的任何行为或了解均不得被视为放弃本协议的任何条件或规定，除非该方正式授权的官员或代表签署书面文件。此外,放弃任何一方对本协议项下任何权利的或未能执行本协议的任何规定在任何时间,或与之有关的研制任何权利,不得视为对本协议项下任何其他权利的放弃或任何违约或未履行合同的其他各方。 13. ARBITRATION 争议和仲裁 13.1 Any dispute, controversy or claim arising out of or relating to this Agreement or to a breach hereof, including its interpretation, performance or termination, shall be resolved through friendly negotiation. 13.1因本协议或违反本协议而产生的或与本协议有关的任何争议或索赔，包括本协议的解释、履行或终止，应通过友好协商解决。 13.2 Should there be no settlement through friendly negotiation, it shall be finally resolved by arbitration. The arbitration shall be conducted in the Singapore. All appointed Arbitrators must be accredited by the Singapore International Arbitration Center The arbitration shall be conducted in English and in accordance with the rules of the Philippine Arbitration Law, and shall be the exclusive forum for resolving such dispute, controversy or claim. The award of the arbitration shall be final and binding upon ALL parties. All arbitration fees and expenses shall be borne by the losing party. 13.2如协商不能解决，应通过仲裁解决。仲裁应在新加坡进行。仲裁应按照新加坡国际仲裁法的规定，以英文进行，并应是解决此类争议、争议或索赔的唯一场所。仲裁裁决是终局的，对各方均有约束力。仲裁费用由败诉方承担。 14. LIMITATIONS 限制 Nothing in this Contract shall constitute the parties as partners, joint-venturers of co-owners, or constitute either party as the agent, employee or representative of the other, or empower either party to act for, bind or otherwise create or assume any obligation on behalf of the other, and neither party shall hold itself out as having authority to do the same. 本合同构成双方作为合作伙伴,合资企业的共同所有者,或构成任何一方的代理人、雇员或代表,或赋予任何一方采取行动,绑定或创建或承担任何义务代表另一方,任何一方应当持有自己有权力做同样的事情。 15. CONFIDENTIALITY 保密条款 15.1 The parties agree not to disclose the terms of this agreement, in whole or in part, or to comment on this agreement or parts hereof, except when required according to indispensable applicable law. 15.1双方同意不披露本协议的全部或部分条款，或对本协议或本协议的部分做出评论，除非根据不可缺少的适用法律的要求。 15.2 Each Party recognizes that the proprietary information relating to the other Party or any of its affiliates, which each Party may learn is the valuable property of the other Party. Each Party acknowledges the need to preserve the confidentiality and secrecy of such information as well as all information regarding the terms and provisions of this Contract. This information includes but is not limited to the existence of this Contract, the designs, drawings, material and manufacturing specifications, trade secrets, as well as financial, business, marketing and product development information (collectively “Confidential Information”). Thus, during and after the Term, not anyone of the parties nor their respective officers, directors, employees, agents and representatives will use or disclose any Confidential Information except as necessary for the operation of the business of this Contract or pursuant to Court Order, or as otherwise required by law or by prior written consent of the Parties. The Parties shall take all reasonable steps necessary to ensure that any permitted use of the Confidential Information preserves such confidentiality and secrecy. The obligations set forth herein shall survive the termination of this Agreement. 15.2双方均承认，与另一方或其任何关联公司有关的专有信息是另一方的宝贵财产，双方均可获知该等信息。双方均承认有必要对该等信息以及与本合同条款和规定有关的所有信息进行保密。该信息包括但不限于本合同的存在、设计、图纸、材料和制造规范、商业秘密以及财务、商业、营销和产品开发信息(统称“保密信息”)。因此,期间和之后,没有任何政党和各自的官员,董事,雇员,代理人和代表将使用或披露任何保密信息,除了必要的操作业务本合同或根据法院命令,或法律另有规定或当事人的事先书面同意。双方应采取一切必要的合理措施，以确保机密信息的任何获准使用均保持该等机密和保密。本协议规定的义务在本协议终止后继续有效。 16. SEVERABILITY 可分割性 In the event that any provision of this Agreement shall be unenforceable or invalid under any applicable law or be so held by applicable court or arbitration decision, such unenforceable or invalidity shall not render this Agreement unenforceable or invalid as a whole except for the part so declared to be invalid or unenforceable. The parties shall consult and use their best efforts to agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid or unenforceable provision in light of the intent of this Agreement. 如果本协议的任何条款根据任何适用法律不可执行或无效，或由适用法院或仲裁决定持有，则此类不可执行或无效不应使本协议无法执行或整体无效，除非声明的部分如此 无效或无法执行。 双方应协商并尽最大努力就有效和可执行的条款达成一致，该条款应根据本协议的意图合理替代此类无效或不可执行的条款。 IN WITNESS WHEREOF, the parties hereto set their hands this on 25th September 2020 at HAIKOU, China 兹证明，本协议三方于2020年9月25日在中国海口市签署本协议。
ANNEX “A” 附件A
Note: All brands and generic counter parts of the subject product included. 注：以上所有产品的品牌药和仿制药均包括在内 ***************************************NOTHING FOLLOWS 以下空白********************************** |
FOREIGN AGENCY AGREEMENT 代理协议 菲律宾
涉外文件格式样本 | 2022-01-08 16:18FOREIGN AGENCY AGREEMENT 代理协议 菲律宾